Welcome!

News Feed Item

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

NEW YORK, April 22, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02051452/Chemotherapy-Induced-Acral-Erythema-Hand-Foot-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 7
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) 31
Apr 20, 2011: Advancell Initiates Clinical Phase IIb Study Of ATH008 In Hand-foot Syndrome 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
F. Hoffmann-La Roche Ltd. 32
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 32
Merck & Co., Inc. 33
Clinical Trial Overview of Merck & Co., Inc. 33
Cahaba Pharmaceuticals 34
Clinical Trial Overview of Cahaba Pharmaceuticals 34
Advancell 35
Clinical Trial Overview of Advancell 35
Clinical Trial Overview of Top Institutes / Government 36
Northwestern University 36
Clinical Trial Overview of Northwestern University 36
Cambridge University Hospitals NHS Foundation Trust 37
Clinical Trial Overview of Cambridge University Hospitals NHS Foundation Trust 37
Asan Medical Center 38
Clinical Trial Overview of Asan Medical Center 38
North Central Cancer Treatment Group 39
Clinical Trial Overview of North Central Cancer Treatment Group 39
Sun Yat-sen University 40
Clinical Trial Overview of Sun Yat-sen University 40
Case Comprehensive Cancer Center 41
Clinical Trial Overview of Case Comprehensive Cancer Center 41
Duke University 42
Clinical Trial Overview of Duke University 42
West Virginia University 43
Clinical Trial Overview of West Virginia University 43
University of California, San Francisco 44
Clinical Trial Overview of University of California, San Francisco 44
University of Wisconsin Madison 45
Clinical Trial Overview of University of Wisconsin Madison 45
Five Key Clinical Profiles 46
Appendix 60
Abbreviations 60
Definitions 60
Research Methodology 61
Secondary Research 61
About GlobalData 62
Contact Us 62
Disclaimer 62
Source 63

List of Tables

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region, 2014* 8
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 11
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 32
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 33
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cahaba Pharmaceuticals, 2014* 34
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Advancell, 2014* 35
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014* 36
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cambridge University Hospitals NHS Foundation Trust, 2014* 37
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Asan Medical Center, 2014* 38
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 39
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 40
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 41
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 42
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by West Virginia University, 2014* 43
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 44
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Wisconsin Madison, 2014* 45

List of Figures
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 11
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 61

To order this report: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02051452/Chemotherapy-Induced-Acral-Erythema-Hand-Foot-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
There is growing need for data-driven applications and the need for digital platforms to build these apps. In his session at 19th Cloud Expo, Muddu Sudhakar, VP and GM of Security & IoT at Splunk, will cover different PaaS solutions and Big Data platforms that are available to build applications. In addition, AI and machine learning are creating new requirements that developers need in the building of next-gen apps. The next-generation digital platforms have some of the past platform needs a...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
Businesses are struggling to manage the information flow and interactions between all of these new devices and things jumping on their network, and the apps and IT systems they control. The data businesses gather is only helpful if they can do something with it. In his session at @ThingsExpo, Chris Witeck, Principal Technology Strategist at Citrix, will discuss how different the impact of IoT will be for large businesses, expanding how IoT will allow large organizations to make their legacy ap...
Adobe is changing the world though digital experiences. Adobe helps customers develop and deliver high-impact experiences that differentiate brands, build loyalty, and drive revenue across every screen, including smartphones, computers, tablets and TVs. Adobe content solutions are used daily by millions of companies worldwide-from publishers and broadcasters, to enterprises, marketing agencies and household-name brands. Building on its established design leadership, Adobe enables customers not o...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
24Notion is full-service global creative digital marketing, technology and lifestyle agency that combines strategic ideas with customized tactical execution. With a broad understand of the art of traditional marketing, new media, communications and social influence, 24Notion uniquely understands how to connect your brand strategy with the right consumer. 24Notion ranked #12 on Corporate Social Responsibility - Book of List.
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more meaningful conversations and was not only happy with the results but also learned a few new things. Here is everything I learned in those three days distilled into three short points.
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, will discuss key challenges and solutions to powering a ride sharing and/or multimodal model in the a...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software sec...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...